Abstract:Background and aims: In cirrhotic patients, the clinical relevance of metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. We aimed to research the relationship between MAFLD and adverse clinical outcomes in patients with hepatitis B cirrhosis. Methods: A total of 439 patients with hepatitis B cirrhosis were enrolled. Abdominal MRI and computed tomography were used to calculate liver fat content in order to evaluate steatosis. The Kaplan-Meier method was implemented to generate survival curves. The independent risk factors for prognosis were identified by multiple Cox regression. Propensity score matching (PSM) was used to reduce the influence of confounding factors. This study explored the relevance between MAFLD and mortality, first decompensation and further decompensation. Results: In our study, most patients were decompensated cirrhosis (n = 332, 75.6%) and the ratio of decompensated cirrhosis patients in non-MAFLD to MAFLD group was 199 : 133. Compared to the non-MAFLD group, patients with MAFLD had worse liver function which mainly reflected that there were more Child-Pugh C patients and higher model for end-stage liver disease score in the MAFLD group. A total of 207 adverse clinical events occurred in the total cohort during a median follow-up of 47 months, including 45 deaths, 28 hepatocellular carcinoma, 23 first decompensation and 111 further decompensation. Cox multivariate analysis showed that MAFLD was an independent risk factor for death [hazard ratio (HR) 1.931; 95% confidence interval (CI) 1.019-3.660; P = 0.044 HR 2.645; 95% CI, 1.145-6.115; P = 0.023] and further decompensation (HR 1.859; 95% CI, 1.261-2.741; P = 0.002 HR 1.953; 95% CI, 1.195-3.192; P = 0.008) before and after PSM. In decompensated group with MAFLD, diabetes had a more significant effect on adverse prognosis than overweight or obesity and other metabolic risk factors. Conclusion: In patients with hepatitis B cirrhosis, concomitant MAFLD can predict a higher risk of further decompensation and death among decompensated individuals. According to patients among MAFLD, diabetes may be a major factor in the occurrence of adverse clinical events.

The Potential Effects of Diabetes Mellitus on Liver Fibrosis in Patients with Primary Biliary Cholangitis

Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: the impact of pre-existing diabetes mellitus.

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

Diabetes Mellitus is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma

Impact of Preexisting Diabetes Mellitus on Outcome after Liver Transplantation in Patients with Hepatitis B Virus-Related Liver Disease

Diabetes Mellitus and Poor Glycemic Control Negatively Impact Clinical Outcomes and Survival in Patients with Compensated Cirrhosis

Liver fibrosis according to diabetes status and relation to cardiovascular risk and mortality in US adults

Clinical Outcomes of Patients with and Without Diabetes Mellitus after Hepatectomy: A Systematic Review and Meta-Analysis

Liver Grafts for Transplantation from Donors with Diabetes: an Analysis of the Scientific Registry of Transplant Recipients Database

Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation.

Impact Of Diabetes Mellitus On The Prognosis Of Patients With Hepatocellular Carcinoma After Curative Hepatectomy

Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease

Post-Transplant Diabetes Mellitus in Liver Transplantation: Hangzhou Experience

Management of Diabetes Mellitus in Patients with Chronic Liver Diseases

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis

The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study

Association between primary biliary cholangitis with diabetes and cardiovascular diseases: A bidirectional multivariable Mendelian randomization study

Association between diabetes mellitus and primary biliary cholangitis: a two-sample Mendelian randomization study

Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases